New Jersey expansion broadens service portfolio currently offered in Maryland.
Dr. DuBey will be responsible for the strategy of the bioanalytical services business as it expands in number of locations, team members, and capabilities.
The Smithers Avanza Toxicology Services Business Unit Acquired by Bioanalytical Systems, Inc. “BASi”
New Jersey laboratory will support client demand for services and will be GLP-, GCP-, GMP-compliant and CLIA certified.
Nadia Kulagina, PhD, appointed as Director of Science and Brian Hoffpauir, PhD, appointed as Director of Operations.
Bioanalytical Services names Robert L. Moore, Ph.D. to the position of Director, Business Development
These instruments, along with the recent additions to the physical lab space, increase Smithers Avanza’s capacity for bioanalytical testing.
With this addition, the company will augment its existing stable of lab instrumentation, allowing for increased efficiency and capacity for testing related to the development and validation of immunoassays that are used during the development of biologics.
Smithers Avanza announced that its Bioanalytical Services Division has completed the second expansion of its bioanalytical laboratory in the last two years.
Smithers Avanza has augmented its capabilities for pharmacokinetics (PK), immunogenicity, and biomarker testing through the addition of the Gyros Gyrolab™ xPS workstation.
Smithers Avanza announced that its Bioanalytical Services Division has Clinical Laboratory Improvement Amendments (CLIA) certification.
In a study of contract research organizations (CROs) around the world, the Pharma’s Almanac recognized Smithers Avanza among the top bioanalytical CROs. Pharma’s Almanac is published quarterly by independent researcher Nice Insight.
New Space & Increased Capacity Will Support Client Requests for Testing of Large Molecule Biotherapeutics